First Personal Financial Services Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

First Personal Financial Services lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 73.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,421 shares of the biopharmaceutical company’s stock after selling 4,006 shares during the quarter. First Personal Financial Services’ holdings in Gilead Sciences were worth $90,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Advisors Preferred LLC purchased a new position in shares of Gilead Sciences during the second quarter worth about $26,000. Weaver Consulting Group purchased a new position in shares of Gilead Sciences during the first quarter worth about $34,000. Legacy Advisors LLC purchased a new position in shares of Gilead Sciences during the second quarter worth about $37,000. Evolution Wealth Advisors LLC purchased a new position in shares of Gilead Sciences during the second quarter worth about $46,000. Finally, Motco grew its holdings in shares of Gilead Sciences by 213.6% during the second quarter. Motco now owns 690 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 470 shares during the last quarter. 79.67% of the stock is currently owned by hedge funds and other institutional investors.

GILD stock opened at $65.54 on Wednesday. The firm has a 50 day moving average of $64.23 and a 200-day moving average of $65.36. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $76.44. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13. The company has a market cap of $82.67 billion, a price-to-earnings ratio of 10.66, a PEG ratio of 3.03 and a beta of 1.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. During the same period last year, the firm earned $1.91 EPS. The company’s revenue for the quarter was down 2.8% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.67 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, September 12th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.84%. Gilead Sciences’s payout ratio is 40.98%.

In other news, EVP Brett A. Pletcher sold 608 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $64.35, for a total transaction of $39,124.80. Following the completion of the transaction, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at approximately $1,750,191.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Olsen Per Wold sold 4,908 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total transaction of $313,670.28. Following the transaction, the director now directly owns 102,762 shares of the company’s stock, valued at $6,567,519.42. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,716 shares of company stock valued at $821,299. Insiders own 0.20% of the company’s stock.

GILD has been the topic of a number of research reports. Jefferies Financial Group set a $95.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. Cantor Fitzgerald set a $88.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday, July 15th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Monday, July 15th. Royal Bank of Canada upgraded shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price objective for the company in a research report on Monday, July 29th. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $85.00 price objective on shares of Gilead Sciences in a research report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $82.24.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: What is the outlook for the FAANG stocks?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.